Patents by Inventor Keld Danø

Keld Danø has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide antagonists of the human urokinase receptor and method for selecting them
    Patent number: 7026282
    Abstract: A novel set of inhibitors of the binding interaction between human urokinase plasminogen activator (uPA) and its cell surface receptor (uPAR) has been developed. The inhibitors comprise of peptide fragments, monomeric or in multiple copies attached to a common scaffold, in which the amino acid sequence may include uncommon substituted amino acids to partially comprise of peptoid sequences. The present invention also relates to the use of such peptides in therapy, in particular for the treatment of cancer, having developed a modified non-human mammalian receptor to which the novel inhibitors are antagonistic.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: April 11, 2006
    Assignee: Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning)
    Inventors: Michael Ploug, Søren Østergaard, Claus Holst-Hansen, Ross Stephens, Keld Danø, Arne Holm
  • Urokinase-type plasminogen activator receptor
    Patent number: 6248712
    Abstract: Activation of plasminogen to plasmin is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator receptor are provided.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: June 19, 2001
    Assignee: Cancerforskningsfondet af 1989
    Inventors: Keld Danø, Francesco Blasi, Ann Louring Roldan, Maria Vittoria Cubellis, Maria Teresa Masucci, Ettore Appella, W.D. Schleuning, Niels Behrendt, Ebbe Rønne, Peter Kristensen, Jari Pöllänen, Eeva-Marjatta Salonen, Ross W. Stephens, Hannele Tapiovaara, Antti Vaheri, Lisbeth Birk Møller, Vincent Ellis, Leif Røge Lund, Michael Ploug, Charles Pyke, Lászl{acute over (o )} Patthy
  • Suppression of inhibitors
    Patent number: 6224865
    Abstract: The present invention relates to methods for inhibiting malignant tumour growth, invasion and/or metastasis in a patient, the method comprising suppressing the inhibitory activity of an inhibitor of a protease or of a non-proteolytic matrix-degrading enzyme (IPNME) in malignant tumour tissue or potential malignant tumour tissue. The suppression may be brought about by administering compounds interacting with the IPNME, but also administration of compounds interacting with transcription of genes encoding the IPNME is a possibility. The invention also relates to methods of selecting and identifying compounds in the therapeutical methods, as well of the use of such compounds in the treatment of malignancies.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: May 1, 2001
    Assignee: Cancerforskningsfonden AF 1989
    Inventors: Nils Brünner, John Rømer, Vincent Ellis, Charles Pyke, Jan Grøndahl-Hansen, Helle Pedersen, Heine Høi Hansen, Keld Danø